<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322619</url>
  </required_header>
  <id_info>
    <org_study_id>054-12</org_study_id>
    <nct_id>NCT02322619</nct_id>
  </id_info>
  <brief_title>Bio-equivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Moxifloxacin Tablets, 400 mg of Dr. Reddy's Laboratories Limited, Comparing With Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc. in Healthy, Adult Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose,&#xD;
      crossover, oral bioequivalence study in human subjects under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose,&#xD;
      crossover, oral bioequivalence study of moxifloxacin tablets 400 mg of Dr. Reddy's&#xD;
      Laboratories Limited, comparing with Avelox ® Tablets 400 mg of Bayer Healthcare&#xD;
      Pharmaceuticals Inc. in healthy, adult, human subjects under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve</measure>
    <time_frame>0.167, 0.333, 0.500, 0.750, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.500, 4.000, 4.500, 5.000, 6.000, 8.000, 10.000, 12.000, 16.000, 24.000, 36.000 and 48.000 post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Moxifloxacin Tablets 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avelox Tablets 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Tablets 400 mg</intervention_name>
    <description>Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Avelox Tablets 400 mg</arm_group_label>
    <arm_group_label>Moxifloxacin Tablets 400 mg</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult human volunteers between 18 to 45 years of age (both inclusive) living&#xD;
             in and around Ahmedabad city or western part of India.&#xD;
&#xD;
          -  Having a Body Mass Index (BMI) between 18.5 to 24.9 (both inclusive), calculated as&#xD;
             weight in kg / height in m2.&#xD;
&#xD;
        Not having any significant diseases or clinically significant abnormal findings during&#xD;
        screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG and&#xD;
        X-ray chest (postero-anterior view) recordings.&#xD;
&#xD;
          -  Able to understand and comply with the study procedures, in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Able to give voluntary written informed consent for participation in the trial.&#xD;
&#xD;
          -  In case of female subjects:&#xD;
&#xD;
               -  Surgically sterilized at least 6 months prior to study participation or&#xD;
&#xD;
               -  If of child bearing potential is willing to use a suitable and effective double&#xD;
                  barrier contraceptive method or intra uterine device during the study. and&#xD;
&#xD;
               -  Pregnancy test must be negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or idiosyncratic reaction to Moxifloxacin, other Quinolones or&#xD;
             any of the excipients or any related drug.&#xD;
&#xD;
          -  History or presence of any disease or disorder known to influence bone metabolism,&#xD;
             compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous,&#xD;
             cardiovascular, immunological, dermatological, gastrointestinal or any other body&#xD;
             system.&#xD;
&#xD;
          -  Ingestion of medicine [including vitamin, herbal supplements and any enzyme modifying&#xD;
             drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes and strong&#xD;
             inducers of CYP enzymes] at any time within 14 days prior to check in of period-I. In&#xD;
             any such case subject selection will be at the discretion of the Principal&#xD;
             Investigator.&#xD;
&#xD;
          -  If the QTc interval will be more than 450 ms on ECG measurement at the time of&#xD;
             screening.&#xD;
&#xD;
          -  Any history or presence of hypokalamia, QT prolongation including torsades de pointe.&#xD;
&#xD;
          -  Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or&#xD;
             NSAIDs induced urticaria.&#xD;
&#xD;
          -  A recent history of harmful use of alcohol(less than 2 years), i.e. alcohol&#xD;
             consumption of more than 14 standard drinks per week for men and more than 7 standard&#xD;
             drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of&#xD;
             wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or&#xD;
             consumption of alcohol or alcoholic products within 48 hours prior to check in.&#xD;
&#xD;
          -  Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from&#xD;
             smoking during the study.&#xD;
&#xD;
          -  The presence of clinically significant abnormal laboratory values during screening.&#xD;
&#xD;
          -  Use of any recreational drugs or history of drug addiction or testing positive in pre&#xD;
             study drug scans.&#xD;
&#xD;
          -  History or presence of psychiatric disorders.&#xD;
&#xD;
          -  A history of difficulty with donating blood.&#xD;
&#xD;
          -  Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal&#xD;
             product or participation in a drug research study within 90 days prior to receiving&#xD;
             the first dose of study medicine.&#xD;
&#xD;
        Note: In case the blood loss was less than or equal to 200 mL; subject may be enrolled 60&#xD;
        days after blood donation or after the last sample of previous study&#xD;
&#xD;
          -  A positive hepatitis screen including hepatitis B surface antigen and/or HCV&#xD;
             antibodies.&#xD;
&#xD;
          -  A positive test result for HIV antibody.&#xD;
&#xD;
          -  Consumption of grape fruit or grape fruit products within 48 hours prior to check in.&#xD;
&#xD;
          -  An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to check&#xD;
             in of Period I. In any such case subject selection will be at the discretion of the&#xD;
             Principal Investigator.&#xD;
&#xD;
          -  Nursing mothers (females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Shashikanth Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Ltd.</affiliation>
  </overall_official>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

